STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Janus Henderson Reports 5.05M Shares in Biohaven; Passive Position

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Janus Henderson Group plc reports beneficial ownership of 5,053,528 shares of Biohaven Ltd. common stock, representing approximately 4.9% of the class. The position is disclosed as shared voting and shared dispositive power held through Janus Henderson subsidiaries that act as registered investment advisers to managed portfolios.

The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Biohaven, and it includes a power of attorney delegating authority to named compliance officers to execute required ownership filings.

Positive

  • Transparent disclosure of an aggregate beneficial position of 5,053,528 shares in Biohaven (~4.9%).
  • Certification that the securities are held in the ordinary course of business and not for the purpose of changing control.
  • Identification of investment-adviser subsidiaries holding shared voting and dispositive power, clarifying the ownership structure.
  • Power of attorney included to ensure timely compliance filings by named compliance officers.

Negative

  • None.

Insights

TL;DR: Janus Henderson holds a passive, sub-5% stake in Biohaven; routine disclosure with limited market impact.

The filing discloses an aggregate holding of 5,053,528 shares (~4.9%) with shared voting and dispositive power. A subsidiary-level breakdown shows JHIUS may be deemed to hold 4,924,530 shares (~4.8%). Because the filer certifies the position is held in the ordinary course and not for control, this is a transparent regulatory disclosure of a material but non-controlling stake. Impact: not impactful on corporate control or immediate valuation.

TL;DR: Filing demonstrates regulatory compliance and delegation of filing authority via power of attorney.

The Schedule 13G/A (Amendment No. 5) includes a certification that holdings are passive and a power of attorney naming specific compliance officers to file and amend ownership reports on behalf of Janus Henderson Group plc. The disclosure of shared voting/dispositive power and the identification of investment-adviser subsidiaries aligns with reporting obligations for institutional investors. Impact: not impactful beyond transparency and regulatory compliance.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



JANUS HENDERSON GROUP PLC
Signature:Kristin Mariani
Name/Title:Head of North America Compliance, CCO
Date:08/14/2025
Exhibit Information

POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

FAQ

How many Biohaven (BHVN) shares does Janus Henderson report owning?

The filing reports an aggregate of 5,053,528 shares beneficially owned, representing approximately 4.9% of the class.

Does Janus Henderson claim voting or dispositive power over these BHVN shares?

Yes. The position is reported with shared voting power and shared dispositive power rather than sole power.

Is this stake reported as intended to influence control of Biohaven (BHVN)?

No. The filing includes a certification that the securities are held in the ordinary course of business and not to change or influence control of the issuer.

Through what vehicles are the shares held?

Holdings are reported as held through Janus Henderson subsidiaries that act as registered investment advisers furnishing advice to managed portfolios.

Does the filing give authority for future SEC ownership filings?

Yes. The document includes a power of attorney appointing named compliance officers to execute and file required ownership and amendment documents on behalf of Janus Henderson.
Biohaven

NYSE:BHVN

BHVN Rankings

BHVN Latest News

BHVN Latest SEC Filings

BHVN Stock Data

1.28B
120.40M
11.55%
82.71%
10.06%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN